Related Experiment Videos
Lonidamine: a non-mutagenic antitumor agent
R Forster1, A Campana, E D'Onofrio
1F. Angelini Research Institute, Rome, Italy.
Abstract:
Lonidiamine is a novel indazole-carboxylic acid with antitumour properties; it has been studied for potential mutagenicity in a comprehensive battery of tests. In assays for the induction of gene mutations in prokaryotes (Ames test) and eukaryotes (induction of HPRT mutations in CHO cells), negative results were obtained. There was no evidence of the induction of chromosomal damage in cultured mammalian cells in vitro. No mutagenic activity was observed in tests for chromosomal damage in vivo, in somatic cells (micronucleus test) or in germinal cells (dominant lethal test). These negative results are consistent with observations indicating that lonidamine affects cellular energy processes, rather than the mechanisms of cell division. The lack of mutagenic properties suggests that lonidamine may present significant advantages in treatment of some tumours, offering a reduced risk of resistant clones, secondary cancer and heritable genetic damage.
Insights
Lonidamine, an antitumour indazole-carboxylic acid, showed no mutagenic activity in comprehensive genetic toxicity tests. This lack of mutagenicity suggests a reduced risk of secondary cancers and heritable genetic damage in cancer patients.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Lonidamine is an indazole-carboxylic acid derivative with demonstrated antitumour properties.
- Assessing the mutagenicity of novel anticancer agents is crucial for patient safety and therapeutic efficacy.
Purpose of the Study:
- To comprehensively evaluate the potential mutagenicity of lonidamine using a battery of in vitro and in vivo genotoxicity assays.
- To determine if lonidamine poses a risk for inducing genetic damage.
Main Methods:
- Bacterial reverse mutation assay (Ames test).
- In vitro mammalian cell assays (HPRT gene mutation, chromosomal aberration).
- In vivo assays (micronucleus test, dominant lethal test).
Main Results:
- Lonidamine tested negative in bacterial gene mutation assays.
- No evidence of gene mutation induction in CHO cells.
- No chromosomal damage observed in vitro or in vivo.
- Negative results in somatic and germinal cell genotoxicity tests.
Conclusions:
- Lonidamine exhibits a lack of mutagenic and genotoxic potential across multiple test systems.
- Its mechanism of action appears to target cellular energy processes, not DNA or cell division machinery.
- The absence of mutagenicity suggests lonidamine may offer therapeutic advantages with a lower risk of secondary malignancies and heritable genetic damage.